RecruitingPhase 1NCT07171034

A Phase I Study of KLA318-2 Nanocrystal Injection

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KLA318-2 Nanocrystal Injection in Healthy Participants


Sponsor

Hunan Kelun Pharmaceutical Co., Ltd.

Enrollment

48 participants

Start Date

Sep 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to evaluate the safety,tolerability and pharmacokinetics properties of KLA318-2 Nanocrystal Injection after a single intravenous injection in healthy participants.


Eligibility

Min Age: 18 YearsMax Age: 45 Years

Inclusion Criteria3

  • Health participants (Age: 18~45 years);
  • Body Weight: Male≥50.0kg, Female≥45.0kg; 18.5 ≤BMI≤ 28.0;
  • Normal ECG, showing no clinically relevant deviations, as judged by the investigator.

Exclusion Criteria18

  • Allergy or Drug hypersensitivity;
  • Clinically significant Medical History;
  • Gastrointestinal ulcers or gastrointestinal bleeding;
  • History of any surgery within 4 weeks;
  • History of any Medication within 14 days;
  • History of any drug interactions with celecoxib within 30 days;
  • History of any clinical study within 3 months;
  • History of any vaccine within 1 month;
  • History of any drug abuse, or positive drugs of abuse test result;
  • Subjects with difficult venous blood collection/intolerance to venipuncture, or with a history of needle phobia/blood phobia;
  • Massive blood loss (> 200 mL) in the past 3 months;
  • Special requirements for diet;
  • Heavy smoker ( more than 3 cigarettes/day) within 3 months;
  • History of alcohol abuse,or heavy alcohol intake (more than 14 units a week) within 6 months, or positive alcohol test;
  • Heavy caffeine intake;
  • History of grapefruit, xanthine-rich foods intake within 7 days;
  • Female participants are pregnant or lactating;
  • History of unprotected sex within 2 weeks.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGKLA318-2 Nanocrystal Injection

Intravenous injection, single dose

DRUGCelebrex Capsule

P.O., single dose


Locations(1)

The first affiliated hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)

Jinan, Shandong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07171034


Related Trials